Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

NVST or BSX: Which Is the Better Value Stock Right Now?

NVST vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes

Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.

Boston Scientific's (BSX) New Buyout to Aid Clot Management

The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.

Abbott's (ABT) Portico With FlexNav System Gets FDA Approval

Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Here's Why You Should Retain Boston Scientific (BSX) for Now

Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.

NVST vs. BSX: Which Stock Should Value Investors Buy Now?

NVST vs. BSX: Which Stock Is the Better Value Option?

Abbott (ABT) Expands Vascular Portfolio With New Acquisition

Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.

Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line

Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.

Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable

Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.

Why Is Boston Scientific (BSX) Down 1.4% Since Last Earnings Report?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NVST vs. BSX: Which Stock Should Value Investors Buy Now?

NVST vs. BSX: Which Stock Is the Better Value Option?

If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Boston Scientific (BSX) Just Overtook the 20-Day Moving Average

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

NVST or BSX: Which Is the Better Value Stock Right Now?

NVST vs. BSX: Which Stock Is the Better Value Option?

Sheraz Mian headshot

Top Research Reports for Amazon, Pfizer & Verizon

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Pfizer Inc. (PFE), and Verizon Communications Inc. (VZ).

Urmimala Biswas headshot

4 Medical Device Stocks Set to Beat This Earnings Season

Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.

OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down

OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.

Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up

Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.

Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View

Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.

Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up

Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.

Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up

Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.

Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised

Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.

IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up

Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up

Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.